Medicinova

MediciNova is a biopharmaceutical company based in San Diego, California, focused on developing novel therapeutics targeting neurology, respiratory, and liver diseases that present significant unmet medical needs. The company's pipeline includes programs such as MN-166 for progressive multiple sclerosis and amyotrophic lateral sclerosis, MN-221 for acute exacerbations of asthma and COPD, and MN-001 for various fibrotic diseases, including liver fibrosis and pulmonary fibrosis.

With an emphasis on innovative treatment solutions, MediciNova aims to address critical health challenges through its research and development efforts. The company is committed to advancing therapies that improve patient outcomes in the areas of neurology, respiratory health, and liver conditions.

Generated from the website